Novabay Pharmaceuticals Inc [AMEX: NBY] slipped around -0.01 points on Tuesday, while shares priced at $0.9 at the close of the session, down -0.83%.
Novabay Pharmaceuticals Inc stock is now 78.42% up from its year-to-date (YTD) trading value. NBY Stock saw the intraday high of $0.93 and lowest of $0.8651 per share. The company’s 52-week high price is 1.25, which means current price is +95.43% above from all time high which was touched on 08/20/25.
Compared to the average trading volume of 3.11M shares, NBY reached a trading volume of 14845503 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Novabay Pharmaceuticals Inc [NBY]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for NBY shares is $0.85 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on NBY stock is a recommendation set at 1.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Ladenburg Thalmann have made an estimate for Novabay Pharmaceuticals Inc shares, keeping their opinion on the stock as Buy, with their previous recommendation back on September 18, 2019. While these analysts kept the previous recommendation, H.C. Wainwright raised their target price to Buy. The new note on the price target was released on July 06, 2018, representing the official price target for Novabay Pharmaceuticals Inc stock. Previously, the target price had yet another drop from $10 to $8, while Laidlaw kept a Buy rating on NBY stock.
The Price to Book ratio for the last quarter was 1.23, with the Price to Cash per share for the same quarter was set at 0.94.
How has NBY stock performed recently?
Novabay Pharmaceuticals Inc [NBY] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 49.82. With this latest performance, NBY shares gained by 39.67% in over the last four-week period, additionally plugging by 42.69% over the last 6 months – not to mention a rise of 49.58% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for NBY stock in for the last two-week period is set at 65.23, with the RSI for the last a single of trading hit 0.1157, and the three-weeks RSI is set at 0.0825 for Novabay Pharmaceuticals Inc [NBY]. The present Moving Average for the last 50 days of trading for this stock 0.6554, while it was recorded at 0.9631 for the last single week of trading, and 0.6244 for the last 200 days.
Novabay Pharmaceuticals Inc [NBY]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Novabay Pharmaceuticals Inc [NBY] shares currently have an operating margin of -146.15% and a Gross Margin at 63.20%. Novabay Pharmaceuticals Inc’s Net Margin is presently recorded at -189.31%.
Novabay Pharmaceuticals Inc (NBY) Capital Structure & Debt Analysis
According to recent financial data for Novabay Pharmaceuticals Inc. ( NBY), the Return on Equity (ROE) stands at -431.59%, highlighting a negative impact on investor capital. The Return on Assets (ROA) is -144.50%, reflecting the company’s efficiency in generating profits from its assets. Additionally, Novabay Pharmaceuticals Inc’s Return on Invested Capital (ROIC) is -188.63%, showcasing its effectiveness in deploying capital for earnings.
Novabay Pharmaceuticals Inc (NBY) Efficiency & Liquidity Metrics
Based on Novabay Pharmaceuticals Inc’s (NBY) latest financial statements, the Debt-to-Equity Ratio is 0.24%, indicating its reliance on debt financing relative to shareholder equity.
Novabay Pharmaceuticals Inc (NBY) Efficiency & Liquidity Metrics
From an operational efficiency perspective, Novabay Pharmaceuticals Inc. (NBY) effectively leverages its workforce, generating an average of -$642142.86 per employee. The company’s liquidity position is robust, with a Current Ratio of 2.85% and a Quick Ratio of 2.63%, indicating strong ability to cover short-term liabilities.
Earnings analysis for Novabay Pharmaceuticals Inc [NBY]
With the latest financial reports released by the company, Novabay Pharmaceuticals Inc posted -5.34/share EPS, while the average EPS was predicted by analysts to be reported at -5.25/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -0.09. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for NBY.
Insider trade positions for Novabay Pharmaceuticals Inc [NBY]
There are presently around $21.27%, or 21.28%% of NBY stock, in the hands of institutional investors.
